Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders.

[Solvonis Therapeutics plc @SolvonisTx]

We're delighted to feature in @thisismoney in today's @MailOnline

SMALL CAP IDEA: Ketamine drip therapy firm is taking on alcoholism

Covers our #AUD (SVN-001 & SVN-002) and #PTSD (SVN-SDN-14) prgrms

🔗 https://t.co/tsOrpdwRUi

@proactive_x @ProfDavidNutt @AnthonyTennyson

[Solvonis Therapeutics plc @SolvonisTx]

Our CEO, @AnthonyTennyson, cuaght up with @ZaksTradersCafe earlier today to provide details on our recent progress in drug discovery for #PTSD and drug development for #AUD

👂have a listen!

@Solvonis @ProfDavidNutt

[The Sunday Roast @RoastPR]

Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS https://t.co/3qKW3bEkOe @Solvonis @SolvonisTx

[Solvonis Therapeutics plc @SolvonisTx]

Hey @SolvonisTx followers

- just a reminder

- we've changed our twitter handle to @Solvonis

- please follow us there for all our latest news

Thanks!

[Solvonis Therapeutics plc @Solvonis]

Proud of our team + partners providing hope in PTSD treatment

Follow our journey: @Solvonis

https://t.co/DTRetKWUch

@PTSDAlliance @PTSDUK @HeadwayUK @MindCharity @ProfDavidNutt

#PTSD #MentalHealthAwareness #HopeThroughScience #NeuroInnovation

[Solvonis Therapeutics plc @Solvonis]

Positive results enable us to advance SVN-SDN-14 towards in vivo studies

https://t.co/DTRetKWUch

#clinicaltrials #TranslationalMedicine #DrugDevelopment #BiotechInvesting #LifeSciences

@ProfDavidNutt @ClinicalTrialsGov @NatureMedicine @ScienceTM @Medscape

[Solvonis Therapeutics plc @Solvonis]

🚀 Positive preclinical results for SVN-SDN-14 in PTSD today

Robust SERT, DAT, NET modulation

Major milestone towards new PTSD therapies

https://t.co/DTRetKWUch

#PTSD #Biotech #DrugDiscovery #BiotechNews

@FierceBiotech @EndpointsNews @NatureBiotech @ProfDavidNutt

[Solvonis Therapeutics plc @SolvonisTx]

Hey @SolvonisTx followers - we've changed our twitter handle to @Solvonis - please follow us there for all our latest news - thanks

[Solvonis Therapeutics plc @SolvonisTx]

PTSD isn’t just psychological — it’s neurological.

Trauma affects serotonin, dopamine & noradrenaline pathways — disrupting mood, memory & stress response.

Solvonis is targeting these systems.

#PTSD #Neurobiology #CNSBiotech #Solvonis $SVNS

[Solvonis Therapeutics plc @SolvonisTx]

Over 300M people will experience #PTSD in their lifetime. Yet first-line treatments fall short.

@SolvonisTx (LSE: SVNS) is developing new medicines for chronic, high-prevalence diseases like PTSD — where effective options remain limited.

#MentalHealth #Solvonis

[Solvonis Therapeutics plc @SolvonisTx]

Solvonis (LSE: SVNS) is aligned with the neursychiatry market reset

- ATAI, CMPS, MNMD, GHRS up 35–75% - Spravato hits $1.3B run rate - RFK Jr. calls for FDA reform
$SVNS Clinically active, capital disciplined, CNS-focused
#Biotech #CNS #AUD #PTSD #505b2 #SVNS #MentalHealth

[Solvonis Therapeutics plc @SolvonisTx]

Solvonis (LSE: SVNS) is advancing SVN‑002, a sublingual esketamine OTF, for mod.-to-severe AUD — ~66% of the 29M US cases - targeting 505b2 to Spravato

Spravato, approved for TRD (~4–6M), hit $320M Q2 sales. J&J now guiding $3B–$3.5B peak.

📈 Bigger need. Clear precedent.

[Solvonis Therapeutics plc @SolvonisTx]

Solvonis is advancing SVN‑002 under the FDA’s 505(b)(2) pathway, referencing J&J’s $1B+ blockbuster Spravato®.

SVN‑002 targets moderate-to-severe #AUD with a differentiated formulation for addiction clinics.

#SVN002 #505b2 #Spravato #AddictionTreatment #Solvonis

[Solvonis Therapeutics plc @SolvonisTx]

AUD is the crisis we keep ignoring.

29.5M Americans meet criteria for AUD

<5% get treatment.

SVN‑002 is our neuroscience-led response:

✔ Novel esketamine therapeutic
✔ Clinic-based
✔ 505(b)(2) path, bridging to Spravato®

#AUD #SVN002 #505b2 #AddictionTreatment #Solvonis

[Solvonis Therapeutics plc @SolvonisTx]

Congrats to @SolvonisTx Chair, Dennis Purcell, on landmark $1.9B @AbbVie–IGI deal

As a Board Director at IGI, he played a key role in one of biotech’s biggest licensing agrmnts of 2025

🔹$700M upfront
🔹$1.225B in milestones
🔹Tiered royalties

Proud to have him lead Solvonis

[Solvonis Therapeutics plc @SolvonisTx]

@SolvonisTx Chair Purcell joins Levin & Papadopoulos for a Lucid Capital Mrkts exclusive

Three of biotechs most influential voices

Must-watch conversation

📅 July 17 | 2PM ET 🎙️ Hosted by Elemér Piros
Proud to have Dennis lead Solvonis
#SVNS #Biotech #AIinBiotech #CNS

[Solvonis Therapeutics plc @SolvonisTx]

29.5M Americans meet criteria for #AlcoholUseDisorder. Just 5% receive treatment.

Time for a new paradigm

SVN‑002 is @SolvonisTx neuroscience-based response — designed for real-world clinical delivery in the #US

#AUD #505b2 #AddictionTreatment #Solvonis

[Solvonis Therapeutics plc @SolvonisTx]

The burden of Severe AUD is staggering & urgent

📊 40M w/ AUD across US UK EU4
➡️ ~13M w/ Severe AUD
💀 300K+ deaths/yr
💷 £27.4B/yr in England alone

@Solvonis_Tx is advancing SVN‑001 — a Phase 3 treatment aiming to change this.

🔗 https://t.co/lsqByp6k4h

$SVNS #AUD #SVN001

[Solvonis Therapeutics plc @SolvonisTx]

Solvonis (LSE: $SVNS) is pleased to announce that @Singer_CM has initiated research coverage.

The note, “Psyching Up for Success”, is authored by Dr. Karl Keegan, Head of Life Sciences Research.

Avail to institutional investors now; public next week.

https://t.co/Fh4NsoYJA0

[Solvonis Therapeutics plc @SolvonisTx]

At Solvonis (LSE: SVNS), USPTO has allowed a core patent (No. 18/838,986) for novel #CNS compounds in our #AI-enabled discovery prgm

-No objections -Indications: depression, stimulant use disorder -US exclusivity to ≥2043
$SVNS #Biotech #MentalHealth

https://t.co/mJWcidcPWr